Dibucaine

For adults and adolescents 12 years of age and older, the standard application for Dibucaine 1% ointment is as follows:

• Topical Skin Irritation: Apply a thin layer to the affected area no more than 3 to 4 times daily. It is critical not to exceed this frequency to minimize the risk of systemic absorption.
• Hemorrhoidal Relief: For external use, apply a small amount (approximately the size of a pea) to the affected perianal area up to 3 or 4 times daily, preferably after bowel movements.
• Maximum Dose: Do not use more than one tube (approximately 30 grams or 1 ounce) of 1% ointment in a 24-hour period. Exceeding this limit significantly increases the risk of life-threatening systemic toxicity.

Dibucaine must be used with extreme caution in children.

• Children under 12 years: Dosage must be determined by a pediatrician. Many experts recommend avoiding Dibucaine in young children altogether due to the high risk of accidental ingestion or excessive absorption through their thinner skin.
• Children under 2 years: Use is generally contraindicated or strictly restricted. There have been reported fatalities in toddlers who accidentally ingested small amounts of Dibucaine ointment.

Renal Impairment

While Dibucaine is primarily metabolized by the liver, its metabolites are excreted renally. In patients with severe renal failure, these metabolites may accumulate. While specific dose adjustments for topical use are not standardized, healthcare providers may suggest less frequent application in patients with end-stage renal disease.

Hepatic Impairment

Because Dibucaine is an amide-type anesthetic metabolized by the liver, patients with significant hepatic impairment (e.g., cirrhosis, hepatitis) are at a much higher risk for systemic toxicity. If Dibucaine must be used, it should be applied to the smallest possible area, and the patient must be monitored closely for signs of CNS depression.

Elderly Patients

Elderly patients often have thinner, more friable skin, which can lead to increased absorption of topical medications. Additionally, age-related declines in hepatic function may slow the clearance of any drug that enters the systemic circulation. Healthcare providers typically recommend using the lowest effective dose for the shortest duration possible in this population.

Proper application technique is essential for safety and efficacy:

1. 1Clean the Area: Before application, gently wash the affected area with mild soap and warm water, then pat dry.
2. 2Apply Thinly: Use only enough ointment to cover the area. Do not 'glob' the medication on.
3. 3Wash Hands: Always wash your hands immediately after application to prevent accidental transfer to the eyes or mouth.
4. 4Avoid Occlusion: Do not cover the treated area with plastic bandages, tight-fitting diapers, or waterproof dressings unless specifically directed by a doctor. Heat and lack of airflow increase absorption into the bloodstream.
5. 5Storage: Store Dibucaine at room temperature (20°C to 25°C / 68°F to 77°F). Keep the tube tightly closed and out of the reach of children—this is a critical safety requirement.

If you miss a dose of Dibucaine, apply it as soon as you remember. However, if it is almost time for your next scheduled application, skip the missed dose and return to your regular schedule. Do not apply double the amount to make up for a missed dose, as this increases the risk of toxicity.

Dibucaine overdose is a medical emergency. Signs of systemic toxicity (Local Anesthetic Systemic Toxicity or LAST) include:

• Dizziness, tinnitus (ringing in the ears), and a metallic taste in the mouth.
• Numbness of the tongue or perioral area.
• Visual disturbances and tremors.
• Seizures, followed by CNS depression (drowsiness, coma).
• Cardiovascular collapse (low blood pressure, slow heart rate, or cardiac arrest).

If accidental ingestion occurs, or if signs of toxicity appear, call 911 or your local emergency services immediately.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or apply to larger areas of the body without medical guidance.

Most patients tolerate topical Dibucaine well when used as directed. However, local reactions at the site of application are relatively common:

• Local Irritation: A mild, transient burning or stinging sensation immediately after application is the most frequently reported side effect. This usually subsides within a few minutes.
• Redness (Erythema): The treated skin may appear slightly flushed or pink due to localized vasodilation or mild irritation.

• Contact Dermatitis: Because Dibucaine is a known allergen, some patients may develop an itchy, red rash at the site of application. This is often a delayed hypersensitivity reaction.
• Pruritus (Itching): Paradoxically, the drug intended to stop itching can sometimes cause localized itching if the patient is sensitive to the base ingredients of the ointment or the drug itself.
• Skin Sloughing: In rare cases of frequent use on sensitive mucous membranes, mild peeling or sloughing of the skin may occur.

• Hypersensitivity Reactions: Systemic allergic reactions, including hives (urticaria) and swelling of the face or throat (angioedema), are rare but possible.
• Methemoglobinemia: This is a rare but life-threatening condition where the iron in hemoglobin is oxidized, preventing the blood from carrying oxygen. Symptoms include cyanosis (bluish skin), headache, fatigue, and shortness of breath.

> Warning: Stop using Dibucaine and call your doctor immediately if you experience any of the following serious symptoms. These may indicate systemic absorption and toxicity:

• Central Nervous System Symptoms: Confusion, extreme nervousness, blurred vision, or tremors. These are often the first signs that too much drug has entered the bloodstream.
• Respiratory Distress: Difficulty breathing or very slow, shallow breathing.
• Cardiac Irregularities: A very slow heart rate (bradycardia) or a feeling that your heart is skipping beats (arrhythmia).
• Seizures: Any involuntary muscle contractions or loss of consciousness.
• Signs of Methemoglobinemia: Bluish or pale skin, lips, or fingernails; severe headache; rapid heart rate; or feeling very lightheaded.

Dibucaine is not intended for long-term use. Prolonged application can lead to:

• Sensitization: The more frequently Dibucaine is used, the higher the risk of developing a permanent allergy to it and other amide-type local anesthetics.
• Skin Atrophy: While less common than with steroids, chronic irritation from repeated anesthetic use can lead to changes in skin texture and integrity.
• Masking of Underlying Conditions: Long-term use may hide the worsening of a condition (like a deepening fissure or an infection) that requires different medical intervention.

There are currently no formal FDA Black Box Warnings for Dibucaine; however, the FDA has issued multiple safety communications regarding the risk of accidental ingestion in children. Small amounts of Dibucaine (as little as a few grams of ointment) can be fatal to a toddler if swallowed. Many clinicians treat the pediatric safety profile of Dibucaine with the same gravity as a Black Box Warning.

Report any unusual symptoms or persistent skin changes to your healthcare provider. If a rash develops, discontinue use until a medical professional can evaluate the site for contact allergy.

Dibucaine is a potent medication that must be handled with care. The most critical safety point is the prevention of systemic absorption. Dibucaine should never be applied to large areas of the body, used for long periods, or applied to skin that is severely broken, blistered, or infected. These conditions allow the drug to bypass the skin's natural barrier and enter the bloodstream at toxic levels.

No FDA black box warnings for Dibucaine are currently active. However, clinical literature emphasizes a 'Red Flag' warning regarding pediatric toxicity. Accidental ingestion of Dibucaine ointment by children has resulted in rapid onset of seizures, cardiorespiratory arrest, and death. Always keep this medication in a locked cabinet or high shelf out of reach of children.

• Allergic Reactions / Anaphylaxis: Patients with a known allergy to other amide-type local anesthetics (like lidocaine) should use Dibucaine with extreme caution, as cross-sensitivity can occur. If you experience swelling of the lips, tongue, or throat, seek emergency care.
• Methemoglobinemia Risk: Local anesthetics, including Dibucaine, have been linked to methemoglobinemia. This risk is higher in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, heart disease, or lung disease. It is also higher in infants under 6 months of age.
• Cardiac Effects: Because Dibucaine blocks sodium channels, it can affect the electrical conduction of the heart if absorbed systemically. Patients with existing heart block or arrhythmias are at higher risk for cardiotoxicity.
• Central Nervous System (CNS) Toxicity: Dibucaine can cross the blood-brain barrier. High systemic levels can cause a biphasic reaction—initial CNS stimulation (tremors, anxiety) followed by profound CNS depression (coma, respiratory failure).

For standard topical use, routine lab monitoring is generally not required. However, in specific scenarios:

• Chronic Use: If used frequently for hemorrhoids, a doctor may perform periodic skin exams to check for sensitization.
• Suspected Toxicity: If systemic absorption is suspected, healthcare providers will monitor blood pressure, EKG (heart rhythm), and potentially blood oxygen levels via pulse oximetry or arterial blood gas (to check for methemoglobinemia).

When used correctly as a topical ointment, Dibucaine does not typically interfere with the ability to drive or operate machinery. However, if you experience dizziness, blurred vision, or drowsiness after application, these may be signs of systemic absorption. You should avoid driving and contact your doctor immediately.

There is no direct interaction between topical Dibucaine and alcohol. However, alcohol is a CNS depressant. If a patient has absorbed toxic levels of Dibucaine, alcohol could theoretically worsen the resulting CNS depression. It is best to avoid excessive alcohol if you are using potent local anesthetics.

Dibucaine does not require a tapering period. You can stop using it as soon as your symptoms resolve. If your symptoms do not improve within 7 days, or if they clear up and occur again within a few days, stop use and consult a physician, as this may indicate a more serious underlying condition.

> Important: Discuss all your medical conditions, especially heart, liver, or blood disorders, with your healthcare provider before starting Dibucaine.

While topical interactions are limited, certain combinations are strictly avoided to prevent additive toxicity:

• Other Amide Local Anesthetics: Using Dibucaine simultaneously with lidocaine patches, prilocaine creams (like EMLA), or bupivacaine injections can lead to additive systemic concentrations. This significantly increases the risk of Local Anesthetic Systemic Toxicity (LAST).
• Class I Anti-arrhythmic Drugs: Medications like mexiletine or tocainide also block sodium channels. Using these with Dibucaine can lead to profound cardiac depression and arrhythmias.

• Methemoglobinemia-Inducing Agents: Drugs such as nitrates (nitroglycerin), sulfonamides (Bactrim), and certain anticonvulsants (phenobarbital, phenytoin) increase the risk of developing methemoglobinemia when used alongside local anesthetics. Healthcare providers must monitor oxygen saturation closely if these are used together.
• Beta-Blockers: Drugs like propranolol can reduce hepatic blood flow, which may slow the metabolism of Dibucaine if it reaches the systemic circulation, leading to higher-than-expected blood levels.
• Cimetidine: This H2-blocker can inhibit hepatic enzymes and reduce liver blood flow, potentially increasing the risk of Dibucaine toxicity in sensitive individuals.

• Hyaluronidase: If Dibucaine were used in a clinical setting alongside hyaluronidase, the anesthetic's spread and absorption would be significantly increased, potentially shortening the duration of action but increasing the risk of systemic entry.
• MAO Inhibitors: While primarily a concern for anesthetics containing epinephrine, some clinicians advise caution when using potent anesthetics in patients on MAOIs due to unpredictable blood pressure responses.

There are no known significant interactions between topical Dibucaine and specific foods. Unlike some oral medications, Dibucaine's absorption is not affected by grapefruit juice or dairy products. However, maintaining adequate hydration is always recommended for general skin health.

• St. John's Wort: As an inducer of certain hepatic enzymes, St. John's Wort could theoretically speed up the metabolism of Dibucaine, though the clinical significance for topical use is likely low.
• Kava and Valerian: These herbal supplements have sedative properties. If Dibucaine is absorbed systemically and causes CNS depression, these herbs could potentially enhance that effect.

• Dibucaine Number: This is a specific lab test used to identify patients with atypical pseudocholinesterase (an enzyme that breaks down certain muscle relaxants like succinylcholine). Dibucaine inhibits normal pseudocholinesterase but not the atypical form. If you are scheduled for surgery, tell your anesthesiologist if you have recently used Dibucaine, though topical use rarely interferes with this specific diagnostic test.
• Methemoglobin Levels: Excessive use of Dibucaine will cause an elevation in methemoglobin levels during a blood gas analysis.

For each major interaction, the primary management strategy is to use the lowest effective dose of Dibucaine and avoid application to broken skin or large areas. If you are taking heart medications or blood thinners, your doctor may choose a different anesthetic.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including those applied to the skin.

Dibucaine must NEVER be used in the following circumstances:

• Known Hypersensitivity: If you have had an allergic reaction (rash, hives, difficulty breathing) to Dibucaine or any other amide-type local anesthetic (such as lidocaine, bupivacaine, or mepivacaine), you must not use this drug. The mechanism is an IgE-mediated or T-cell mediated immune response that can lead to anaphylaxis.
• Application to the Eyes: Dibucaine is extremely irritating to ocular tissues and can cause severe corneal damage or numbness that prevents the natural blink reflex, leading to injury.
• Ingestion: As previously noted, oral ingestion is strictly contraindicated and often fatal in pediatric populations.
• Deep Wounds or Severe Burns: Using Dibucaine on denuded skin (skin where the top layer is missing) allows for rapid, uncontrolled systemic absorption, bypassing the protective stratum corneum.

Conditions requiring a careful risk-benefit analysis by a physician include:

• G6PD Deficiency: These patients are at a significantly higher risk for methemoglobinemia because their red blood cells cannot easily revert oxidized hemoglobin back to its functional state.
• Severe Liver Disease: Because the liver is the primary site of amide anesthetic metabolism, patients with cirrhosis or hepatitis may experience toxic accumulation even with 'normal' topical doses.
• Heart Block: Patients with pre-existing conduction defects (like 2nd or 3rd-degree heart block) may experience worsening of their condition if the drug is absorbed systemically.
• Pregnancy and Lactation: Use should be limited to cases where the benefit clearly outweighs the potential risk to the fetus or infant.

Patients should be aware of cross-sensitivity. If you are allergic to 'Caine' anesthetics found in sunscreens, throat lozenges, or other hemorrhoid creams (like benzocaine or lidocaine), you may also react to Dibucaine. While Dibucaine is an amide and benzocaine is an ester, some patients exhibit sensitivity to both classes, particularly when the reaction is contact dermatitis.

> Important: Your healthcare provider will evaluate your complete medical history, including any previous reactions to dental numbing agents or topical creams, before recommending Dibucaine.

Dibucaine is classified as FDA Pregnancy Category C. This means that animal reproduction studies have not been conducted, and there are no adequate and well-controlled studies in pregnant women.

• Trimester-Specific Risks: There is no specific data suggesting teratogenicity (birth defects) in humans, but systemic absorption could theoretically affect fetal heart rate or uterine blood flow.
• Clinical Recommendation: Dibucaine should be used during pregnancy only if clearly needed and under the direct supervision of a healthcare provider. Many doctors prefer using lidocaine during pregnancy as it has a more extensively documented safety profile.

It is not known whether Dibucaine is excreted in human milk. However, many drugs are secreted in breast milk in small amounts.

• Risk-Benefit: The risk to the nursing infant is likely low if the mother applies the ointment to a small area and avoids the nipple/breast area to prevent direct ingestion by the baby.
• Precaution: Nursing mothers should consult their doctor before use and monitor the infant for any signs of unusual sleepiness or poor feeding.

Dibucaine is NOT recommended for use in infants and young children without strict medical supervision.

• Approved Age: While some OTC labels provide instructions for children over 12, use in children under 12 is generally discouraged.
• Toxicity Risk: Children have a higher surface-area-to-body-mass ratio, meaning they absorb more drug relative to their size than adults. Fatalities have occurred from both accidental ingestion and excessive topical application in the pediatric population.

• Pharmacokinetic Changes: Older adults may have reduced hepatic blood flow and slower enzyme activity, which can prolong the half-life of Dibucaine if absorbed.
• Skin Integrity: Thinning of the skin (atrophy) common in the elderly can lead to increased drug penetration.
• Polypharmacy: Elderly patients are more likely to be on beta-blockers or anti-arrhythmics, increasing the risk of drug-drug interactions. Doctors usually recommend the smallest possible dose.

While the kidneys are not the primary site of metabolism, they are responsible for excreting the metabolites. In patients with a GFR (Glomerular Filtration Rate) below 30 mL/min, there is a theoretical risk of metabolite accumulation. No specific dose adjustment is usually required for short-term topical use, but caution is advised for chronic application.

This is a major concern for Dibucaine safety.

• Child-Pugh Classification: Patients with Child-Pugh Class B or C should avoid Dibucaine if possible. If no alternative exists, the frequency of application should be reduced (e.g., once daily instead of four times daily) to allow the liver more time to process the drug.

> Important: Special populations require individualized medical assessment. Never share your medication with others, especially children or those with chronic health conditions.

Dibucaine is a potent local anesthetic that works by stabilizing the neuronal membrane. It binds specifically to the alpha-subunit of voltage-gated sodium channels (Nav1.5 and other subtypes) on the internal surface of the nerve cell membrane. By binding to these channels, Dibucaine prevents the large transient increase in permeability to sodium ions that is required for the generation and conduction of nerve impulses.

Unlike ester anesthetics, which are rapidly broken down, Dibucaine’s quinoline-amide structure allows it to remain at the receptor site longer. It also has a 'use-dependent' block, meaning it binds more effectively to channels that are frequently opening and closing (as they do when transmitting pain signals).

• Onset of Action: When applied topically to mucous membranes or broken skin, the onset of anesthesia is rapid, usually occurring within 2 to 5 minutes. On intact skin, it may take longer (15-30 minutes) to penetrate the stratum corneum.
• Duration: Dibucaine is one of the longest-acting topical anesthetics, with effects lasting 3 to 4 hours, and sometimes up to 6 hours depending on the vascularity of the site.
• Tolerance: There is no evidence of pharmacological tolerance (tachyphylaxis) with occasional topical use.

| Parameter | Value |

|---|---|

| Bioavailability | Low (Intact skin); High (Mucosa/Broken skin) |

| Protein Binding | ~70-75% (Primarily to Albumin and AAG) |

| Half-life | ~3 to 4 hours (Systemic) |

| Tmax | 15-60 minutes (Topical application) |

| Metabolism | Hepatic (Cytochrome P450 system) |

| Excretion | Renal (>90% as metabolites) |

• Molecular Formula: C20H29N3O2
• Molecular Weight: 343.46 g/mol
• Solubility: Slightly soluble in water; very soluble in alcohol, ether, and oils. This high lipid solubility is key to its potency.
• Structure: It is a 2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide. The quinoline ring distinguishes it from the more common benzene-ring amides like lidocaine.

Dibucaine is classified as an Amide-type Local Anesthetic. Within the broader therapeutic area of anesthesiology, it is grouped with lidocaine, bupivacaine, and ropivacaine. However, in the context of dermatology and allergy, it is a Standardized Chemical Allergen [EPC] used for diagnostic purposes.